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Brief Report
ABSTRACT
Resistance to chemotherapy-induced cell death represents a major obstacle in the treatment of acute myeloid leukemia. APRIL (A Proliferation Inducing
Ligand) is a member of the tumor necrosis factor superfamily that plays a key role in normal B-cell development, while promoting survival and prolifer-
ation of malignant B cells. We investigated APRIL expression and activity in acute myeloid leukemia. We found that APRIL mRNA and protein, including
the secreted form, are expressed in leukemic cells of patients with M0, M2 and M4 acute myeloid leukemia subtypes but not in normal hematopoiet-
ic progenitors. Retrovirus-mediated APRIL expression in normal hematopoietic progenitors confers resistance to chemotherapeutic drugs-induced apop-
tosis. Conversely, blocking APRIL function by recombinant soluble APRIL receptors increased chemotherapeutic drugs-induced cell adeath in acute
myeloid leukemia cells. These results indicate that APRIL acts in an autocrine fashion to protect acute myeloid leukemia cells from drug-induced death
and foresee a therapeutic potential of APRIL antagonists in the treatment of acute myeloid leukemia.
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Introduction 
A key issue in the treatment of acute leukemia is the devel-
opment of resistance to chemotherapy. The identification of
the molecular mechanisms promoting the survival of
leukemic cells is a mandatory step to improve the efficacy of
therapeutic approaches. APRIL (a proliferation-inducing lig-
and), is a member of the TNF superfamily expressed in B-cell
progenitors, monocytes, dendritic cells, and megakaryoblasts,
which may contribute to the development of B-cell malignan-
cies, including non-Hodgkin’s lymphoma (NHL), B-CLL and
multiple myeloma (MM), through the enhancement of cell
survival and proliferation.1-6 APRIL is a homotrimeric type 2
transmembrane protein that also exists in soluble form deriv-
ing from the intracellular cleavage of the full-length protein. It
can bind with high affinity to two members of the TNF-
receptor superfamily, the B-cell maturation antigen (BCMA)
and the transmembrane activator and calcium modulator and
cyclophilin ligand-interactor (TACI).1,7,8 However, APRIL
binding was also shown on cells lacking known receptors,
suggesting the existence of another specific interaction.1, 8,9 In
B-cell malignancies, the autocrine production of APRIL con-
tributes to cancer cell survival and resistance to therapeutic
drugs, as indicated by the increased sensitivity to dexametha-
sone and flavopiridol observed after neutralization of APRIL
expression in B-lymphoma and B-CLL cells, respectively. The
chemoresistance acquired by B-CLL cells through the expres-
sion of APRIL prompted us to study its involvement in the
increased survival of acute myeloid leukemia (AML) cells. We
show that AML blasts express considerable levels of APRIL
protein and that its expression results in increased resistance
to drug-induced apoptosis. APRIL neutralization, combined
with chemotherapeutic drugs, leads to cell death induction in
AML cells. 
Design and Methods
Cell purification, culture and transduction
CD34+ hematopoietic progenitors were purified by peripheral
blood as described.9 To induce unilineage granulocytic differenti-
ation, CD34+ cells were cultured in serum-free medium supple-
mented with growth factors as previously described.10 Leukemia
cells were obtained from the peripheral blood of adult patients
with AML diagnosed at IOM (Catania, Italy) after obtaining their
informed consent. Mononuclear cells (MNCs) were prepared by
Ficoll-Paque density centrifugation. Cells were cultured in RPMI
supplemented with 10% fetal bovine serum (GIBCO). Purity of
blasts was assessed by staining with fluorescein isothiocyanate
(FITC)-conjugated anti-CD34. All samples considered in this
study were > 95% CD34+. APRIL cDNA was cloned into the
pcDNA3.1 (by Invitrogen) or PINCO retroviral vector carrying
the green fluorescent protein (GFP) as a reporter gene.9 Cell infec-
tion and sorting were performed as previously described.9
©F
er
ra
ta
 S
t
rti
Fo
un
at
ion
Real time PCR and immunoblot analysis
Total RNA was extracted from cells with RNeasy Mini
kit (Qiagen) and 1 µg RNA was reverse-transcribed by
using High Capacity cDNA Reverse Transcription Kit and
oligo dT (Applied biosystems). Real Time quantitative
PCR was performed as described.9 Gene expression val-
ues were reported as relative percentages using CD34+
cells as reference control. Commercial ready-to-use
primers/probe mixes were used (Assay-on-Demand Gene
Expression products, Hs00601664_g1; Applied Bio-
systems). For immunoblotting, protein extracts were pre-
pared by resuspending cell pellets in 1% nonidet P-40
lysis buffer and analyzed in equal amounts. Immunoblots
were probed with rabbit anti-APRIL polyclonal antibody9
and with anti-actin monoclonal antibody (Sigma). For
flow cytometry analysis of APRIL expression, cells were
incubated for one hour on ice in PBS/1% BSA and with
monoclonal anti-APRIL antibody (Aprily-1 Alexis),
washed and incubated with a fluorescein isothiocyanate
(FITC)-conjugated antimouse secondary antibody (Invi-
trogen-Molecular Probes, Eugene, OR, USA).
Drug treatment
Cells were seeded at a density of 1×105 cells/mL and
incubated in the presence of chemotherapeutic agents. A
series of dose-ranging studies were performed: 50-200
ng/mL for etoposide and camptothecin, 20-80 µM for Ara
C and 5-20 µM for daunorubicine. Choice of the final
drug doses was based on the sensitivity of the different
subtypes of AML. The dosages were used in combination
with 5 µg/mL APRIL blocking receptors, BCMA-Fc and
TACI-Fc or Fn14-Fc (Alexis). Cells were incubated
overnight and viability was determined by both trypan
blue exclusion and acridin orange/ethidium bromide
staining, followed by fluorescence microscopy analysis. 
Results and Discussion
We evaluated the expression of APRIL mRNA in 15
AML samples (>95% CD34+ blast cells), in normal
hematopoietic CD34+ progenitors (HPCs), and in early
granulocytic precursors generated from normal HPCs
cultured in serum-free medium containing interleukin-3,
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Figure 1. APRIL expression at mRNA and protein level in acute
myeloid leukemia blasts. (A) Real-time PCR analyses of acute
myeloid leukemia blasts as compared to normal CD34+ cells and
early granulocytic precursors (G) obtained after five days of unilin-
eage culture. Normal CD34+ cells were used as reference. Data are
mean ± standard deviation of 15 patients in triplicate. (B) Immuno-
blot analysis of APRIL expression in CD34+ and acute myeloid
leukemia cells. 293T cells overexpressing APRIL cDNA were used as
positive control (293T APRIL). APRIL full-length (APRIL) and soluble
forms (sAPRIL) are indicated. Two representative samples for each
acute myeloid leukemia subtype (M0, M2 and M4) are shown. (C)
Flow cytometry analysis of acute myeloid leukemia blasts labeled
with anti-APRIL antibody (right panels) as compared to isotype con-
trol staining (left panels). Two samples for each acute myeloid
leukemia subtype are shown.
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GM-CSF and G-CSF.10 Real-time PCR analysis showed
APRIL mRNA expression in all AML samples, including
5 cases of M0, 5 cases of M2 and 5 cases of M4 subtype
by FAB classification, whereas normal CD34+ HPCs and
early granulocytic precursors did not express APRIL
(Figure 1A). APRIL expression was confirmed by
Western blot analysis, which showed the presence of
both full length and soluble forms of the APRIL protein
in AML blasts (Figure 1B). We next performed immuno-
fluorescence experiments to determine the expression
pattern of APRIL in myeloid leukemia blasts. In 21 cases
analyzed, a significant percentage of the cells were
stained by anti-APRIL antibodies (Figure 1C). The per-
centage of positive cells varied, being higher in the M4
and M2 subtypes than in M0 blasts (Figure 1C). In addi-
tion, we evaluated APRIL expression by FACS analysis in
other FAB subtypes, including 2 M3 and 2 M5 (Online
Supplementary Figure S1A). Overall, these data indicate
that APRIL expression is specifically found in myeloid
leukemia cells, with the exception of M3, but not in nor-
mal CD34+ cells or early granulocytic precursors. The
anti-apoptotic activity showed by APRIL in B-CLL, sug-
gests that the acquisition of APRIL expression in AML
may generate an autocrine loop that could contribute to
the leukemia transformed phenotype. To directly evalu-
ate the pro-survival effect of APRIL expression on AML
cells, we competitively inhibited APRIL activity with an
excess of recombinant soluble receptors. Neutralization
of the APRIL circuit resulted in significant induction of
cell death in all the AML samples, particularly in the M2
subtype (Figure 2A), suggesting that APRIL acts as a sur-
vival factor in myeloid leukemia cells. To investigate
whether APRIL neutralization results in AML cell apop-
tosis, we next evaluated annexin-V/7AAD staining on 3
different M2 samples treated for 24 hours with the
blocking reagents. This treatment induced a considerable
increase in annexin-V binding (Online Supplementary
Figures S1B and S1C), indicating that constitutive expres-
sion of APRIL protects AML cells from apoptosis. Such
an anti-apoptotic activity of APRIL in AML cells might
contribute to the increase in resistance to chemotherapy.
To investigate this hypothesis, we analyzed the cell
death response of 15 fresh AML samples treated with
etoposide or camptothecin, two widely used DNA-dam-
APRIL and AML chemosensitivity
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Figure 2. APRIL promotes the survival of acute myeloid leukemia
cells. (A) acute myeloid leukemia blasts of different subtypes were
treated with 5 µg TACI-Fc and 5 µg BCMA-Fc (BCMA/TACI-Fc) or 10
µg Fn14-Fc recombinant soluble receptors. After 24 hours, cell
viability was evaluated with acridin orange/ethidium bromide
staining and fluorescence microscopy analysis. (B) Acute myeloid
leukemia samples were treated for 24h with 50 ng/mL of etopo-
side (Eto), 200ng/mL of camptothecin (Cam), 40 µM of cytosine
arabinoside (AraC) or 10 µM of daunorubicin (DAU). Data are
mean ± SD of 15 patients in triplicate, 5 for each subtype.
*0.01<p<0.05; **p<0.01 two-tailed t-test. (C) Immunoblot analy-
sis of CD34+ cells transduced with the PINCO empty vector (P1) or
the PINCO vector containing APRIL cDNA (P1APRIL). (D) CD34+
cells transduced with P1 and P1APRIL were treated with camp-
tothecin, etoposide, daunorubicin and AraC. Cell viability was eval-
uated with trypan blue counting after 12 hrs. of treatment. Data
are mean ± s.d of three independent experiments in triplicate.
Figure 3. APRIL downstream signaling. (A) Western blotting of
CD34+ cells transduced with P1 and P1APRIL. (B) Acute myeloid
leukemia blasts of M2, M4 and M0 subtypes were treated with 5
µg/L TACI-Fc and 5 µg/L BCMA-Fc (BCMA/TACI-Fc) recombinant
soluble receptors and lysated after 24 hrs. One representative of
three independent experiments is shown.
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aging drugs. We treated the cells in vitro with either drug
in the presence or absence of competing soluble APRIL
receptors. The results indicate that inhibition of APRIL
signaling significantly increased the apoptotic cell death
induced by etoposide or camptothecin, independently of
the subtype of the leukemia samples (Figure 2B). These
data prompted us to study whether APRIL blocking
agents have a synergistic effect with chemotherapeutic
drugs currently used in AML. We, therefore, treated
leukemia samples representative of the M0, M2 and M4
subtype with cytosine arabinoside (AraC) or daunoru-
bicin, in the presence or absence of APRIL soluble recep-
tors. As for others chemotherapeutic drugs, the block of
APRIL significantly enhanced the induction of cell death
by AraC or daunorubicin, independently of the AML
subtype (Figure 2B). These data suggest that APRIL activ-
ity is part of AML blast response to cytotoxic agents and
may play a relevant role in protecting the cells from cell
death induced by exogenous stimulation, possibly con-
tributing to chemotherapy resistance. To confirm that
APRIL upregulation increases the resistance to chemo-
therapeutic drugs in myeloid progenitors, we transduced
CD34+ HPCs with the retroviral PINCO vector carrying
the APRIL gene together with a green fluorescent protein
(GFP) reporter.9 After flow cytometry sorting, the virtual-
ly pure (>98%) transduced population was analyzed for
APRIL expression, which was comparable with that
observed in AML samples (Figure 2C and data not shown).
In line with the results obtained in AML cells, exogenous
APRIL expression in primary HPCs conferred a signifi-
cant protection from etoposide, camptothecin, daunoru-
bicin, and AraC treatment (Figure 2D). The anti-apoptot-
ic protein Bcl-2 is induced by APRIL in B-cell lym-
phoma.2,3 Since high Bcl-2 expression is associated with
poor chemotherapy response,11,12 we investigated the
relationship between APRIL and Bcl-2 in AML. Western
blotting analysis showed that exogenous expression of
APRIL up-regulated Bcl-2 in CD34+ cells, whereas APRIL
neutralization resulted in Bcl-2 downregulation in pri-
mary AML cells (Figure 3A, B), suggesting that APRIL
protects AML from chemothereutic drugs through the
upregulation of Bcl-2. Thus, APRIL expression promotes
the resistance to chemotherapy of normal myeloid pro-
genitors, while APRIL neutralization considerably
increases the cytotoxic activity of chemotherapeutic
drugs against AML blasts. Transgenic expression of
APRIL under the control of the lck distal promoter
induces the generation of lymphoid tumors in aged
mice,13 indicating that the aberrant expression of APRIL
in hematopoietic cells may promote the tumorigenic
transformation. The antiapoptotic activity of APRIL has
been previously demonstrated in B-lymphoma, multiple
myeloma and B-CLL cells, but may be relevant in other
cancers. In this study, we demonstrate that APRIL
increases the resistance of AML cells to etoposide, camp-
tothecin, daunorubicin, and AraC treatment, possibly by
the upregulation of Bcl-2. Such an ability to promote the
resistance to chemotherapeutic drugs in AML suggests a
general oncogenic role for APRIL in hematologic malig-
nancies. Biotechnology companies are devoting intense
efforts to develop therapeutic molecules that target
autoreactive or malignant B cells through the neutraliza-
tion of APRIL or its partner Blys in autoimmune diseases,
non-Hodgkin’s lymphoma, multiple myeloma and B-
CLL.8,14 In xenograft models of lung and colon cancer,
intratumoral delivery of soluble BCMA was able to sig-
nificantly reduce tumor growth.8 The increased cell
death induced by chemotherapeutic drugs in AML cells
upon inhibition of the APRIL circuit suggests that phar-
macological strategies aimed at blocking of APRIL activ-
ity may considerably improve the efficacy of chemother-
apeutic drugs in myeloid leukemia. 
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